[Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].

德诺苏马布 医学 唑来膦酸 骨转移 兰克尔 乳腺癌 肿瘤科 骨吸收 转移 内科学 癌症 破骨细胞 癌症研究 骨质疏松症 受体 激活剂(遗传学)
作者
Shunji Takahashi
出处
期刊:PubMed [National Institutes of Health]
卷期号:39 (1): 89-94 被引量:3
链接
标识
摘要

Breast cancer is known to be associated with a high incidence of bone metastases. Recent advances in treatment for breast cancer have improved patient prognosis, including those with bone metastasis, highlighting the importance of treating bone metastasis to reduce incidence of skeletal complications and to improve patients' QOL. Currently, bisphosphonates(BP), which are recommended by domestic and international clinical practice guidelines, are commonly used for the treatment of bone metastasis. However, the outcomes of BP therapy leave room for improvement in regard to their efficacy, safety, and convenience. Prior studies have indicated that RANK ligand(RANKL), a cytokine mainly expressed in osteoblasts and bone marrow stromal cells, plays an important role in bone resorption by osteoclasts, which are key mediators in the formation and progression of bone metastasis. Denosumab is a fully human monoclonal anti-RANKL antibody which suppresses differentiation, activation, and survival of osteoclasts by inhibiting the binding of RANKL to its receptor, RANK. In a phase III clinical trial, denosumab significantly decreased the time-to-first and time-to-first-and-subsequent skeletal related events(SRE), compared with zoledronic acid in advanced breast cancer patients with bone metastases. Further more, denosumab was more effective than zoledronic acid in preventing the progression of bone pain and maintaining patients QOL. In the future, treatment of bone metastases for breast cancer patients is expected to evolve further with the introduction of denosumab, which is conveniently administered by subcutaneous injection.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
369ninja发布了新的文献求助10
刚刚
刚刚
乐乐的应助被小杨采纳,获得10
刚刚
Yuan88发布了新的文献求助10
刚刚
1秒前
所所的应助被公爵采纳,获得10
1秒前
3秒前
chloe完成签到 ,获得积分10
3秒前
Yuan88发布了新的文献求助10
3秒前
4秒前
4秒前
小鱼关注了科研通微信公众号
4秒前
枫叶完成签到,获得积分10
5秒前
西瓜汁发布了新的文献求助10
5秒前
5秒前
李健的应助被Lu采纳,获得10
5秒前
上官若男的应助被科研通管家采纳,获得10
6秒前
drizzle发布了新的文献求助10
6秒前
华仔的应助被科研通管家采纳,获得10
6秒前
科目三的应助被科研通管家采纳,获得10
6秒前
Ava的应助被科研通管家采纳,获得10
6秒前
隐形曼青的应助被科研通管家采纳,获得10
7秒前
7秒前
null的应助被科研通管家采纳,获得10
7秒前
Akim的应助被kaia采纳,获得10
7秒前
打打的应助被科研通管家采纳,获得10
7秒前
Hello的应助被科研通管家采纳,获得10
7秒前
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
顾矜的应助被科研通管家采纳,获得10
7秒前
fan的应助被科研通管家采纳,获得20
7秒前
钟小先生完成签到 ,获得积分10
7秒前
汉堡包的应助被科研通管家采纳,获得10
8秒前
DW的应助被科研通管家采纳,获得10
8秒前
王富贵发布了新的文献求助10
8秒前
脑洞疼的应助被科研通管家采纳,获得30
8秒前
完美世界的应助被科研通管家采纳,获得10
8秒前
8秒前
科目三的应助被科研通管家采纳,获得10
8秒前
pluto的应助被科研通管家采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184220
求助须知:如何正确求助?哪些是违规求助? 9573266
关于积分的说明 21830447
捐赠科研通 7781246
什么是DOI,文献DOI怎么找? 3434248
关于科研通互助平台的介绍 2558373
邀请新用户注册赠送积分活动 2480784